Graphical Abstract Highlights d Lipophilic statins and lipophilic bisphosphonates are potent vaccine adjuvants d Modulation of post-translational protein prenylation confers adjuvanticity d Decreased protein prenylation augments antigen preservation and presentation d Statin-or bisphosphonate-mediated vaccination synergizes with anti-PD1 against cancer
INTRODUCTION
Adjuvanticity, the ability of non-antigenic molecules to modify immune responses, is important in vaccine development (Di Pasquale et al., 2015; Reed et al., 2009) . Ideally, an adjuvant should induce a robust response for prophylaxis against infectious diseases such as influenza and would also boost the efficacy of vaccines for non-infectious disease applications, such as cancer (Couzin-Frankel, 2013; Melero et al., 2014; van der Burg et al., 2016) . However, there are just four Food and Drug Administration (FDA)-approved adjuvants: aluminum salts (a.k.a. ''alum''), whose adjuvanticity was discovered some 90 years ago, and MF-59, AS03, and AS04, each of which was approved for human use in the last 10 years. Alum is currently the only widely used adjuvant in public health vaccination efforts (Marrack et al., 2009 ). This paucity of new adjuvants arises in large part from our limited exploration of new adjuvant mechanisms and a consequent lack of druggable targets.
The mevalonate (MVA) pathway is a core metabolic pathway for multiple cellular processes including cholesterol biosynthesis and protein post-translational prenylation (Goldstein and Brown, 1990) . Mevalonate kinase (MVK), an essential enzyme in the MVA pathway, catalyzes the phosphorylation of mevalonate. Patients carrying loss-of-function mutations of MVK develop immunestimulatory phenotypes, such as periodic fever, increased inflammatory cytokine production, and elevated serum immunoglobulin (Ig) levels (Drenth et al., 1999; Haraldsson et al., 1992) . These autoinflammatory phenotypes suggest that the MVA pathway modulates inflammatory responses. This led us to hypothesize that targeting the MVA pathway might boost immunity. Were that the case, it would present a new strategy, based on rationally selected targets, for discovering novel vaccine adjuvant regimens and, potentially, for developing cancer immunotherapies.
The MVA pathway is the pharmacological target of statins and bisphosphonates, drugs used to treat, respectively, hypercholesterolemia (Thompson and Taylor, 2017) and bone disorders (Russell, 2011) . Using synthetic chemistry and extensive screening, we gathered strong evidence that lipophilic statins and bisphosphonates are potent vaccine enhancers. These adjuvants exert their immune-regulatory functions independently of conventional danger sensing and inflammasome activation. Our results indicate that the adjuvanticity is biochemically unrelated to the terminal cholesterol-lowing effects; rather, it is dependent on protein prenylation, a post-translation modification event regulated by the MVA pathway. We demonstrate that these adjuvants inhibit the formation of the downstream metabolite geranylgeranyl diphosphate (GGPP) that is required for geranylgeranylation of small GTPases (e.g., Rab5) in antigen presenting cells. The decrease in this specific lipidation of Rab5 results in arrested endosomal maturation, prolonged antigen retention, enhanced antigen presentation, and T cell activation.
We thus illustrate a unique approach to enhance antigen immunogenicity by modulating antigen preservation in the antigen-presenting cells in the absence of direct innate immune activation. The adjuvanticity associated with MVA pathway inhibition covers multiple arms of immunity, including Th1 and cytolytic T cell responses and is thus suitable for cancer immunotherapies. Our research represents one of the few examples of rational selection of a drug target from the phenotype of a rare disease. The discovery also pharmacologically recontextualizes lipophilic statins and bisphosphonates as well as the MVA pathway itself and presents a new approach for the development of both vaccine adjuvants and cancer immunotherapies.
RESULTS

Lipophilic Statins Are Potent Vaccine Adjuvants
We first evaluated statins as possible vaccine adjuvants. Statins inhibit HMG-CoA reductase, an early stage enzyme in the MVA pathway (Goldstein and Brown, 1990) . The statin family of drugs comprises naturally occurring and synthetic members, which differ in their lipophilicity and potency. We immunized C57BL/ 6 mice with ovalbumin (OVA) admixed with a panel of 12 chemically diverse statins (structures shown in Figures S1A and S1B) and then measured total serum OVA-specific IgG titers after 14 days. Lipophilic statins (e.g., simvastatin) triggered strong immune responses (Figure 1A) , with serum IgG endpoint titers $703 higher than OVA alone and 53 higher than an alumboosted control. Polar statins, in contrast, did not enhance antibody titers beyond the level of the alum control ( Figure 1A) , likely because of their weak membrane permeability (average clogP of 0.4 versus 3.8 for the lipophilic statins). Further, we found that while the polar (hydrophilic) statin pravastatin was rapidly cleared from muscle, the lipophilic statin simvastatin persisted at a high level for 5 hr before gradually tapering off (Figure S1C) . It is noted that the local concentration is a required pharmacokinetic premise for immune-boosting effects of small molecule adjuvants (e.g., as seen with TLR-7 agonists) (Wu et al., 2014) .
We verified the adjuvanticity of simvastatin by confirming its ability to induce increased germinal center formation (Figure 1B) . We also compared simvastatin with adjuvants that are currently in clinical use or in active trials: alum, MF59 (a squalene-oil mixture), MPL (monophosphoryl lipid A, the main component of AS04), imiquimod (a TLR-7 agonist) (Meyer and Stockfleth, 2008) , and polyethyleneimine (Wegmann et al., 2012) , and found that simvastatin induced the highest IgG titers ( Figure 1C ) and antibody avidity index values (Figure 1D) . Simvastatin was also able to increase antibody titers against the haptenized experimental antigen nitrophenol-conjugated keyhole limpet hemocyanin (NP-KLH) ( Figure S1D ), as well as influenza A/PR8 hemagglutinin A1 (HA1), HBV surface antigen (HBsAg), and HPV16 E7 (E7) (Figures S1E-S1G). The immune response induced by simvastatin was also long-lasting ( Figure S1H ). Moreover, the adjuvanticity of simvastatin was not influenced by vaccine delivery route ( Figure S1I ). Of note, in cynomolgus monkeys, the HA1-specific serum IgG titers of the simvastatin group were 73 higher than in the alum group (Figure S1J) .
We next evaluated the prophylactic efficacy of simvastatin in a highly pathogenic influenza virus-challenge model . Challenged with an otherwise lethal dose of PR8 virus, simvastatin-antigen (HA1)-immunized mice were completely protected, whereas control mice that received either no HA1 or HA1 alone had severe (20%-30%) weight loss ( Figure 1E ), high disease scores ( Figure 1F ), 100% mortality (Figure 1G) , and extensive lung tissue damage (Figure 1H ). This prophylactic efficacy was consistent with the high HA1 serum IgG titers observed in HA1 antigen assays (Figure S1E ). Similar prophylactic efficacy was also observed in mice that received adoptively transferred splenocytes from simvastatin-HA1-immunized donor mice (Figures S1K and S1L) . In contrast, simvastatin alone did not confer any protection to C57BL/6 mice ( Figures S1M and S1N ). (A) OVA-specific immunoglobulin (IgG) titers of mice (C57BL/6 strain, if not otherwise specified) on day 14 after intramuscular (i.m.) immunization with OVA (100 mg) and each of 12 statins (100 mg) (n = 5). (B) Fluorescence-activated cell sorting (FACS) analysis of B220 + GL7 + Fas + germinal center B cells on day 10 after i.m. immunization with OVA (100 mg) alone, with simvastatin (100 mg) or alum (2 mg). (C) OVA-specific IgG titers on day 14 after immunization with OVA (100 mg) alone or admixed with simvastatin (100 mg), MPL (100 mg), imiquimod (100 mg), polyethylenimine (PEI) (100 mg), alum (2 mg), or a squalene water emulsion (MF59) (50 mL) (n = 5). (D) IgG avidity index measured by ELISA using NaSCN on day 21 after immunization (boosted with 50 mg of OVA on day 7 and 14) (n = 5). (E-H) Protection of vaccinated mice from pathogenic influenza virus challenge. Mice (n = 10) were immunized with the HA1 subunit of PR8 (5 mg) alone, with simvastatin (20 mg), with alum (2 mg), or with MF59 (50mL) and boosted with HA1 (5 mg) on days 14 and 21, followed by challenge with live PR8 virus on day 28. Days shown on the x axis are after the viral challenge. Shown are weight loss (E) , disease score (F) , and Kaplan-Meier survival plot (G). Histopathological analysis (H&E staining) of mouse lungs on day 5 post virus challenge (scale bar represents 100 mm) (H). Shown are a single representative experiment of three (A-D) or four (E-H) independent experiments. Data were analyzed by using two-way ANOVA (F) or two tailed unpaired t test (A, C, D) . Survival plot data were analyzed by using a log-rank (Mantel-Cox) test (G). NS, not significant, *p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 0.0001. All error bars denote SEM. See also Figures S1 and S2.
It should also be noted that simvastatin-mediated vaccination is tolerable in C57BL/6 mice, as revealed by its negligible effects on mice body weight ( Figure S2A ), survival ( Figure S2B ), gross organ anatomy ( Figure S2C ), as well as immune cell subtype distribution in splenocytes (Figure S2D ) and DLNs ( Figure S2E ). Collectively, these results demonstrate the performance of a lipophilic statin as an adjuvant and suggest a causal link between inhibition of the MVA pathway and the induction of adaptive immunity.
Modulation of Post-translational Protein Prenylation Confers the Adjuvanticity of Mevalonate Pathway Inhibitors
To address the biochemical mechanism underlying the effects of statins on immunity-given that the target of statins (HMG-CoA reductase) is an early enzyme in the MVA pathway-we next explored the possibility that inhibitors of downstream enzymes ( Figure 2A ) might also function as adjuvants. Nitrogen-containing bisphosphonates are drugs used to treat bone resorption diseases and are inhibitors of farnesyl diphosphate synthase (FPPS) (Figure 2A ). We screened a panel of 8 bisphosphonate drugs (structures shown in Figure S3A ) including zoledronate (Zometa, Novartis), the most active FPPS inhibitor. These drugs did not, however, exhibit adjuvanticity comparable to simvastatin ( Figure S3B ). This is most likely due to their high polarity (average clogP <À3), an undesirable pharmacokinetic property for small molecule adjuvants (Wu et al., 2014) , as seen with the polar statins ( Figure 1A ).
We thus designed TH-Z93, a lipophilic bisphosphonate (Figure 2B) as an FPPS inhibitor (IC 50 = 90 nM). An X-ray crystal structure of TH-Z93 bound to FPPS (PDB: 5YGI) ( Figure S3C ; Table S1 ) showed that the two phosphonates bind to a [Mg 2+ ]3 cluster, the nitrogen atoms mimic the cationic transition state of FPPS (Martin et al., 1999) , and the n-hexyl side chain binds to the hydrophobic cleft, thereby contributing to FPPS inhibition. The n-hexyl side chain significantly increases its hydrophobicity (clogP value of À1.3 for TH-Z93 versus À3.8 of zoledronate). Unlike conventional bisphosphonate drugs ( Figure S3B ), the rationally designed TH-Z93 exhibits potent efficacy, increasing both antibody titers and avidity ( Figure 2C ).
The early-stage MVA pathway enzymes HMG-CoA reductase (targeted by statins) and FPPS (targeted by TH-Z93) produce farnesyl diphosphate (FPP). After FPPS, the pathway bifurcates, leading via squalene synthase to cholesterol or via geranylgeranyl diphosphate synthase (GGPPS) to GGPP; the latter is required for the post-translational protein modification called geranylgeranylation. To determine which branch is involved in the adjuvanticity of statins and TH-Z93, we synthesized a lipophilic GGPPS inhibitor, TH-Z145 (GGPPS IC 50 = 210 nM) (Figure 2B) . This compound is a very lipophilic bisphosphonate (C) OVA-specific IgG titers and avidities of mice on day 14 after immunization with OVA (100 mg) or in combination with different MVA pathway inhibitors (n = 4). (D) Effect of co-administration of GGPP (100 mg) with different adjuvants on OVA-specific IgG titers on day 14 after immunization with OVA (n = 5). (E) Synergistic effect of simvastatin and bisphosphonates (50 or 100 mg). OVA-specific IgG titers were detected on day 14 after immunization (n = 5). All experiments were repeated at least three times. Data were analyzed by using a two-tailed unpaired t test (C-E) . NS, not significant, **p < 0.01 and ***p < 0.001. All error bars denote the SEM. See also Figure S3 . that lacks the cationic center essential for FPPS inhibition and is thus a specific GGPPS inhibitor (FPPS IC 50 >30 mM). We also used a known cholesterol-lowering agent (BPH-652) ( Figure 2B ) to specifically inhibit squalene synthase (SQS) . The use of HMG-CoA reductase, FPPS, SQS, as well as GGPPS inhibitors enables a determination of the biochemical basis for adjuvanticity. Chemical inhibition of SQS did not induce any adjuvant effect ( Figure 2C ), precluding the involvement of squalene or any of its downstream metabolites (e.g., cholesterol, steroids) in adjuvanticity. In contrast, TH-Z145 triggered strong adjuvant responses ( Figure 2C ). Both TH-Z93 and TH-Z145 exhibited strong prophylactic effects in a pathogenic influenza model ( Figures S3D-S3G ).
Importantly, co-administration of GGPP during vaccination (by-passing GGPPS inhibition) with any of the three MVA pathway inhibitors (simvastatin, TH-Z93, and TH-Z145) abolished all of the adjuvant effects in mice ( Figure 2D ). The MVA pathway inhibitors must therefore confer their vaccine adjuvant effects by inhibiting GGPP biosynthesis. Taken together, modulation of post-translational protein geranylgeranylation, but not cholesterol lowering, seems to be a key mechanism by which statins and bisphosphonates alter immune functions. On the other hand, when simvastatin was used in combination with each of the two other inhibitors, a boost of antibody titers was found ( Figure 2E ). This effect suggests a more complete MVA pathway blockage that led to an enhanced adjuvanticity.
The Adjuvanticity of Simvastatin Is Independent of Conventional Danger Sensing and Pyrin Inflammasome Activation A major function of adjuvants is activation of innate immune responses that trigger adaptive immunity in which antigenpresenting cells (APCs) play an important role. We thus studied a well-established mode of adjuvant mechanism-direct action of APCs to increase cytokine secretion and expression of co-stimulatory molecules. Bone marrow-derived dendritic cells (BMDCs) were incubated in vitro with either simvastatin or lipopolysaccharide (LPS). In sharp contrast to LPS, the MVA pathway inhibitors, represented by simvastatin (henceforth, data of TH-Z93 and TH-Z145 are not shown for simplicity) did not upregulate CD80, CD86, or major histocompatibility class-II (MHC-II) ( Figures S4A-S4C ), nor did it induce cytokine release ( Figure S4D ). This suggested that the adjuvanticity of simvastatin was achieved via another route-distinct from conventional pathogen-associated molecular pattern (PAMP)-driven immune-enhancing effects.
The pathogenesis of MVK deficiency is reported to be driven by pyrin (encoded by gene Mefv) inflammasome activation (Akula et al., 2016; Park et al., 2016) . Robust interleukin (IL)-1b production did occur in wide type but not in ASC À/À , Caspase 1 À/À /11 À/À , and Mefv À/À BMDCs ( Figure S4E ) that were pretreated with simvastatin followed by addition of LPS. However, OVA-specific IgG titers did not differ among wide type, Myd88 À/À ;Trif Lps2/Lps2 , Mefv À/À , ASC À/À and Caspase 1 À/À 11 À/À mice ( Figure S4F ) upon simvastatin-OVA vaccination. Therefore, the involvement of pyrin inflammasome in simvastatin's adjuvant effect was excluded in our experimental system despite the reports that pyrin is an innate immune sensor regulated by the MVA pathway (Park et al., 2016) , and inflammasome (NLRP3) is involved in alum's adjuvanticity (Eisenbarth et al., 2008) .
Simvastatin Increases Antigen Presentation via Prolonged Antigen Preservation during Endocytosis
To identify the pathways in BMDCs that were regulated by statins, we performed a bottom-up proteomics investigation. Simvastatin prominently regulates proteins involved in endocytic processing ( Figure 3A ; Table S2 ). For example, simvastatin treatment increased the levels of TSG101 and VAMP3, proteins involved in endocytic vesicle trafficking and organization (Buzas et al., 2014) , and the levels of TUBB2A, a protein required for the co-assembly of microtubule scaffolds (Sirajuddin et al., 2014) ( Figure S5A ).
We next found that simvastatin increased antigen presentation of BMDCs to both CD4 + and CD8 + T cells ( Figure 3B ). In vivo, CD69 expression on both CD4 + and CD8 + T cells was also increased, confirming the effect of simvastatin on both types of T cell response ( Figure S5B ). For both cross-presentation to CD8 + T cells and soluble antigen presentation to CD4 + T cells, antigens are internalized via the endo/phagocytic pathway (Neefjes et al., 2011) . When this pathway is used for endocytic degradation in macrophages and neutrophils, protein cargos are rapidly degraded. In DCs, however, this maturation process is delayed, resulting in prolonged and enhanced antigen presentation. This feature is critical for DCs' extraordinary capacity to activate the adaptive immunity (Alloatti et al., 2015; Delamarre et al., 2005; Savina et al., 2006) . Simvastatin treatment significantly slowed down endosome maturation ( Figure 3C ). While simvastatin did not alter OVA uptake ( Figure S5C ), the treatment dramatically increased the retention time of OVA in DCs both in vitro (Figures 3D and 3E) and in vivo ( Figure 3F ). Simvastatin treatment also prolonged the availability of a model endocytic cargo (FITC-dextran) in DLNs following its local (i.m.) delivery ( Figure S5D ).
Prolonged antigen retention in the endocytic system is expected to increase the availability of antigenic epitopes, resulting in more abundant MHC/peptide complexes on the cell surface (Joffre et al., 2012) . Several assays were set up for detailed verifications. First, OVA-loaded and simvastatin-treated DCs were fixed and were used to stimulate OT-1 and OT-II cells. In this case, costimulatory molecules and secretion factors are not involved, the stimulatory intensity is proportional to the amount of pMHC on the cell surface (Rosalia et al., 2013) . Treated DCs showed high potency in both assays ( Figure 3G ). Second, we determined the number of epitope peptides complexed with MHC on the cell surface by extracting these peptides from BMDCs and quantified their levels in an antigen presentation assay (Shi et al., 1998) . Simvastatin-treated BMDCs showed higher recovery of the peptides ( Figure 3H ), with an increase of 4-to 8-fold per titration analysis. Third, quantitative mass spectroscopic analysis supported enhanced SIINFEKL sequences on DCs following simvastatin treatment ( Figure 3I ; Table S3 ). Fourth, a direct staining of class I (OVA257-264/Kb) pMHCs using complex-specific antibodies (25D1) indicated the increased surface presence of this epitope ( Figure 3J ). Taken together, these four independent assays confirm that a primary mechanism of simvastatin's adjuvanticity comes from its ability to increase the surface availability of antigenic epitopes.
Mevalonate Pathway Inhibitors Block the Rab5 Lipidation Required for Endosomal Trafficking
Consistent with the idea that simvastatin's adjuvant effects are consequences of an altered GGPP metabolism, the addition of GGPP abolished simvastatin's ability to slow BMDC endosomal trafficking ( Figure 4A ) and its ability to increase antigen presentation ( Figure 4B ). To further characterize the role of GGPP deprivation in DCs, we crossed CD11c-cre transgenic mice with homozygous floxed GGPPS mice to obtain a mouse model with DC-specific GGPPS gene deletion (40%-50% deletion efficiency) ( Figure 4C ). In these mice, vaccination with OVA alone resulted in higher IgG titers than in the controls ( Figure 4D ), supporting a role of GGPP in DCs depletion in simvastatin's adjuvant effect. GGPPS deletion also resulted in substantial reduction of endosome and lysosome fusion ( Figure 4E ). As expected, GGPPS deficiency also recaptured the effect of simvastatin in antigen presentation ( Figure 4F ).
The results shown in Figure 4C indicate that DCs serve as a conduit in simvastatin's adjuvanticity. In order to determine if other cell types also contributed to the effect, we first treated both CD4 + and CD8 + T cells alone with simvastatin. In contrast to DC stimulation, direct treatment on these responder cells did not show any enhanced activation ( Figure S5E ). We next tested the role of macrophages by clodronate liposome-mediated macrophage depletion, along with CD11c-DTR/diphtheria toxin-mediated DC depletion. The clodronate liposome experiments removed $50% of the macrophages, but anti-OVA titers remained unchanged, while there was near total loss of antibody titers after DC removal by DT ( Figures S5F-S5I ). Due to the limitations of these depletion technologies as well as the lack of markers that precisely define DCs, we cannot rule out the involvement of macrophages, but DCs most likely shoulder the ''lion's share'' of simvastatin's adjuvanticity.
Geranylgeranylation increases the affinity of proteins for biological membranes and is thus a major ''on-off switch'' for controlling protein/membrane association. As small GTPases such as Rab GTPases-key players in intracellular organelle dynamics and endosomal trafficking-are regulated by this process (Seabra and Wasmeier, 2004) , we conducted a screen of BMDCs using a focused small interfering RNA (siRNA) library targeting Rab4, Rab5, Rab7, Rab11, and Rab35 (Stenmark, 2009 ). Knockdown of Rab5 ( Figure 5A ) interrupted endosomal trafficking ( Figure 5B ) and increased antigen presentation (Figure 5C) . Simvastatin decreased the amount of Rab5 localized to membranes and increased the amount in the cytosol (Figure 5D ). Moreover, co-administration of simvastatin with GGPP restored the normal cellular distribution of Rab5 ( Figure 5D ). These results are consistent with the observation that mevalonate kinase deficiency leads to decreased prenylation of Rab GTPase (Jurczyluk et al., 2016) . We thus propose that simvastatin functions by inhibiting the formation of GGPP that is required for geranylgeranylation of small GTPases (including Rab5) in APCs, resulting in arrested endosomal maturation, prolonged antigen retention, increased antigen presentation, and T cell activation.
Mevalonate Pathway Inhibitors Are Suitable for Cancer Vaccination and Synergize with Anti-PD-1 Antibodies
Although alum has been used as an adjuvant for over 90 years, its applications are limited due to its inability to induce the Th1 immunity (Coffman et al., 2010 ) that confers protection against many pathogens and is an essential attribute for use in cancer immune therapies. We then performed a subtype analysis of IgG antibodies. Simvastatin-OVA vaccination resulted in a far higher IgG2c response (marker for Th1 immunity) than did alum in C57BL/6 mice ( Figure 6A ). Moreover, OVA re-stimulation strongly induced Th1 cytokine production in lymphocytes from DLNs of mice immunized with simvastatin-OVA ( Figure 6B ), as well as enhancing lymphocyte cell proliferation ( Figure 6C ). An in vivo cytotoxicity analysis (Clemente et al., 2013) conducted 28 days after OVA vaccination showed that simvastatin-treated (C) GGPPS deletion efficiency and specificity in immune cells isolated from GGPPS fl/fl /CD11c-cre and CD11c-cre mouse spleen and peritoneal cavity. (D) OVA-specific IgG on day 14 from GGPPS fl/fl /CD11c-Cre and CD11c-Cre mice immunized with OVA (100 mg) (n = 5). (E) Endosome maturation in BMDCs of CD11c-Cre mice or GGPPS fl/fl /CD11c-Cre mice (scale bar represents 10 mm). (F) CD4 + and CD8 + T cell IFN-g secretion and T cell proliferation in response to OVA presentation by BMDCs of CD11c-Cre mice or GGPPS fl/fl /CD11c-Cre mice. Shown is one representative experiment of two (C) or three (A, B, D-F) independent experiments. Data were analyzed two-tailed unpaired t tests. NS, not significant, *p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 0.0001. All error bars denote the SEM. mice had a stronger ability than did alum in killing OVA-bearing cells ( Figure 6D ). Tetramer staining showed that 1% of CD8 + T cells were positive for the OVA-tetramer in simvastatin-immunized mice, higher than in the alum or CpG adjuvant controls ( Figure 6E ). These experiments demonstrate that simvastatin has the ability to induce a full spectrum of immune responses, with Th1 coverage and cytolytic T cell responses being highly sought after in cancer vaccine development.
We next tested its potential use in therapeutic vaccinations against tumors. In the B16-OVA (melanoma) model, simvastatin-OVA vaccination significantly reduced tumor volumes, (Figures 6F and 6G) , and extended the median lifespan from 23 to 34 days ( Figure 6H ). Similar results were obtained in the TC-1 model of human papillomavirus-associated tumors . Simvastatin alone failed to exhibit anti-B16 and anti-TC-1 tumor effects in nude mice, indicating that the above anti-cancer efficacy arises from immune-modulation rather than a direct cancer cell killing by simvastatin ( Figures S6A  and S6B ). Moreover, adoptive transfer of splenocytes from simvastatin-OVA immunized mice showed tumor-resistance to OVA-bearing B16 tumor ( Figures S6C and S6D ). In addition, the adoptive transfer of Trp2-pulsed, simvastatin-pretreated DCs dramatically blocked the growth of pre-established B16-F10 tumors ( Figure S6E ).
In the B16-OVA tumor model, the anti-tumor effect was significantly reduced in the presence of the anti-CD4 antibody and almost completely eliminated in the presence of anti-CD8 antibodies ( Figures S6F and S6G ), while natural killer (NK) cell depletion did not have any significant effect ( Figures S6H and S6I ). The tumor-therapeutic effect observed here was likely the result of a classic combined CD4 + /CD8 + T cell response without involving NK cells. Likewise, simvastatin-OVA vaccination also greatly increased tumor-infiltrating CD4 + and CD8 + T cells ( Figure S6J ).
We finally investigated the potential of combination therapies with an anti-PD-1 antibody. Indeed, a treatment that combined simvastatin-antigen vaccination with later administration of an anti-PD-1 antibody dramatically increased the survival rates of B16-OVA ( Figures 7A-7C ) and TC-1 ( Figures 7D-7F ) inoculated mice. In the TC-1 model, all of the TC-1 tumor-free mice that received the combination treatment were resistant to re-challenge with TC-1 cells ( Figures 7G and 7H) . These results suggest that simvastatin-antigen vaccination contributes to a host-specific immunological memory response. Similar cancer vaccination efficacies were also seen with TH-Z93 and TH-Z145, the FPPS and GGPPS inhibitors ( Figure S7 ).
DISCUSSION
Progress in human vaccine adjuvant discovery has been slow compared to all other areas of modern medicine. The concept of immunological adjuvant, referred to as the ''immunologist's dirty little secrets'' (Janeway, 1989) , is based on the disturbance in immune homeostasis triggered by innate signaling, accompanied by various forms of inflammation. The immune system recognizes PAMPs via pathogen-recognition receptors (PRRs), including toll-like receptors (TLRs), cytosolic nucleotide oligomerization domain-like receptors (NODs), retinoic acid-inducible gene-based-I-like receptors (RIG-I), and C-type lectin-like receptors (Reed et al., 2009 ). These PAMPs are the main components of some adjuvants. In other adjuvant regimens, such as alum, water/oil emulsions, and particulate delivery vehicles, the precise role of innate recognition is less characterized. They nevertheless rely on the modulation of a core set of genes that control cytokine signaling, chemotaxis, inflammatory cell recruitment, and activation of antigen-presenting cells (Mosca et al., 2008) . To a large extent, our guiding principles for adjuvant discovery have been based on the ''Danger Model'' of innate immunity. In vaccination, extracellularly delivered antigens are eventually displayed as epitopes in complex with MHC molecules on the cell surface. This transition involves several critical cellular functions, such as extracellular cargo uptake, endocytic processing, and MHC loading (Blum et al., 2013) . Whether these events can be manipulated via pharmacological means to enhance host immune responses is an intriguing proposal.
In this work, we demonstrated the adjuvanticity of lipophilic statins and bisphosphonates in multiple animal models, excluded the involvement of pyrin inflammasome activation, and showed that statins mediate immune enhancement in ways that are distinct from conventional ''danger sensing''based adjuvants. Instead, inhibition of the MVA pathway prevents the production of GGPP, a metabolite that is required for the geranylgeranylation of small GTPases such as Rab5 in dendritic cells; this ultimately results in arrested endosomal maturation, prolonged antigen retention, enhanced antigen presentation, and T cell activation. Of note, we are not able to definitively exclude the possibility that simvastatin might also limit the geranylgeranylation of other small GTPases to confer adjuvanticity and have not made formal investigation into how these lipidation events contribute to the endosomal antigen retention. It is known that some other Rab (Agola et al., 2011) and Rho family members (Qualmann and Mellor, 2003) might also regulate cargo sorting and endosome trafficking. The members of the Rho subfamily of small GTPases that contain one C terminus CAAX motif are also susceptible to geranylgeranylation. Thus, the regulated endosome trafficking observed in DCs by simvastatin might be an integrated outcome of inhibition of geranylgeranylation of Rab5 and a collection of additional small GTPases. Inhibitors of the MVA pathway at steps prior to production of GGPP delays endosomal antigen entry into degradative lysosomes, thus enhancing antigen presentation. This key discovery provides the first confirmation that manipulation of endocytic maturation can be used as a strategy to enhance immune activation in the absence of overt inflammatory signals.
The MVA pathway has been extensively studied for many years, and it has been thought that the inhibition of this pathway by drugs like statins results in immuno-suppressive effects. This idea was initially proposed based on clinical observations of the protective effects of statins on endothelial functions and organ transplantation, as well as myocardial infarction and stroke (Hebert et al., 1997; Jain and Ridker, 2005; Kobashigawa et al., 1995; Vaughan et al., 1996) . At the cellular level, early reports suggested that statins decreased cytokine-mediated activation of co-stimulatory gene expression in microglia (Youssef et al., 2002) , macrophages (Kwak et al., 2000) , or in DCs (Yilmaz et al., 2004) . These observations led to an impression that statins might suppress antigen-presentation abilities (Greenwood et al., 2006) . Ghittoni et al. (2006) claimed that tetanus toxoid processing and presentation in DCs was impaired by simvastatin. However, how much cytokine-mediated APC activation contributes to broad immune induction needs additional parsing and whether statin suppression on DC antigen presentation can be generalized from a microbial toxoid alone has yet to be confirmed.
There is considerable evidence available to challenge views that statins and disruption of the mevalonate metabolism invariably result in immunosuppression. One example is that patients with the genetic disease of MVK deficiency have obvious symptoms of immune-stimulation. Furthermore, statins have been reported to sensitize myeloid cells to external stimuli like LPS and to produce cytokines (Akula et al., 2016; Park et al., 2016) . Gruenbacher et al. (2010) reported that IL-2 co-stimulation enabled statin-mediated activation of human NK cells. In a clinical study, it was reported that simvastatin treatment induced an increase in autoantibodies against oxLDL, and this induction was accompanied by an expansion of CD8 + T cells (Gonç alves et al., 2009) . Collectively, these findings question the simple conclusion that inhibition of the MVA pathway is immune-suppressive and raise interesting questions about possible context-dependent effects.
Regarding potential observational discrepancies, we did notice that simvastatin was reported by Ghittoni et al. (2006) to suppress tetanus toxoid processing and presentation to CD4 + T cells at a concentration 20 times than ours; at this Figure 7 . Simvastatin Synergizes with Anti-PD-1 Therapy (A-C) In B16-OVA model a-PD-1 (100 mg per mouse per injection) was injected intraperitoneally twice-a-week following vaccination, as indicated by the red arrows (n = 10). Shown are tumor volume post-inoculation (A), representative IVIS images acquired on post-inoculation day 21 (B) , and Kaplan-Meier survival plots (C) . (D-F) Combination of simvastatin and a PD-1 blocking antibody in TC-1 model (n = 10). Shown are tumor volume (D) , representative IVIS images acquired on postinoculation day 24 (E) , and Kaplan-Meier survival plot (F) . (G and H) Tumor-free mice in sim-E7 + a-PD-1 group were re-challenged (on day 100 after the first round of tumor cell inoculation) with 3 3 10 5 TC-1 tumor cells (n = 6). Shown are tumor volume post inoculation (G) and Kaplan-Meier survival plot (F) . All data are representative of at least three independent experiments. Tumor volume data were analyzed with two-way ANOVA (A, D, G) and survival data were analyzed with a log-rank (Mantel-Cox) test (C, F, H). **p < 0.01 and ****p < 0.0001. All error bars denote the SEM. See also Figure S7 . concentration, severe APC death was noted in our lab (data not shown), and some unintended toxicities may have contributed to reduced immune responses in some assays. In addition to our work, a previous study reported that short-term atorvastatin treatment enhanced specific antibody production following tetanus toxoid vaccination in healthy volunteers (Lee et al., 2006) , suggesting that human data may not support the findings from the cellular experiments of Ghittoni et al. (2006) . There is a relative paucity of evidence demonstrating clear-cut vaccination (immune) boosting effects in populations taking statins. This can be explained from at least two angles. First, the oral administrations of statins (as applied in general populations) would not generate an optimized environment pertinent to strong immune activations-optimized environments are often in peripheral/ parenchymal tissues rather than in gastrointestinal tracts. Second, in light of our findings that lipophilic, but not polar statins (and bisphosphonates), confer significant adjuvant effects, the temporal accumulation of a locally concentrated adjuvant in combination with antigens appears to be essential to induce adaptive immune responses (Wu, 2016) .
Inhibiting the MVA pathway in APCs strongly enhances both Th1 and cytolytic T cell responses that are lacking in clinical adjuvants. The MVA pathway should thus now be viewed as a rational, druggable target for vaccine adjuvant discovery and cancer immunotherapies. In addition, the synergistic effect in combination with anti-PD1 checkpoint therapy should be most welcome in cancer immunotherapy. Clinical researchers have long reported that some cancer therapy outcomes are significantly improved in patients taking statins and bisphosphonates (Gronich and Rennert, 2013) . In a recent epidemiologic analysis of 312,907 patients, use of statins alone and in combination with bisphosphonates provided survival benefits in certain cancers (El-Refai et al., 2017) . Our results with multiple MVA pathway inhibitors in multiple cancer models offer new insights to help interpret these reported clinical benefits, and additional clinical investigations based on our discoveries are thus warranted.
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STAR+METHODS KEY RESOURCES
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Mice
Strain /Species
The mice used in this work include C57BL/6 mice (purchased from Vital River, China), OT-I (C57BL/6-Tg (TcraTcrb)1100Mjb/J) and OT-II (B6.Cg-Tg(TcraTcrb)425Cbn/J) transgenic mice (purchased from the Jackson Laboratory), ASC À/À mice (C57BL/6 N), Mefv À/À mice (C57BL/6), Caspase1 À/À /11 À/À mice (C57BL/6), Trif lps2/lps2 mice (C57BL/6J-Ticam1Lps2/J), Myd88 À/À mice (C57BL/6), CD11-Cre mice (B6.Cg-Tg(Itgax-cre)1-1Reiz/J) and CD11c-DTR transgenic mice (B6.FVB-Tg-Itgax-DTR/EGFP-57Lan/J). The ASC À/À , Mefv À/À , Caspase1 À/À /11 À/À , Trif lps2/lps2 , Myd88 À/À , CD11-Cre and CD11c-DTR transgenic mice were gifts from our collaborators as indicated in the Acknowledgments. In addition, Myd88 À/À ;Trif lps2/lps2 double knock out mice were generated by crossing Myd88 À/À and Trif lps2/lps2 mice. DC-specific GGPPS knock-out mice were generated by crossing CD11c-Cre mice and GGPPS fl/fl mice (B6;129-GGPPS tm1MARC ; purchased from the Model Animal Research Center of Nanjing University, China). Age/gender Both male and female mice of 6 to 10 weeks of age were used. In each independent experiment, all animals used were sex and age matched. Health/immune status The mice were kept under SPF conditions in our animal facilities that are regularly checked for standard pathogens per general husbandry protocols.
Whether subjects were involved in previous procedures
The animal used in this work received no prior treatment before the indicated experimental procedures. Whether the subject is drug or test naive Mice used for all experiments were naive. No drug tests and prior vaccinations were done. Husbandry and housing conditions All mice were bred and housed at Tsinghua University Animal Facilities (12 h light/dark cycle, lights on at 7:00 a.m.) in groups of 2-5 with free access to food and water under specific pathogen-free conditions. All animal protocols used in this study are approved by the IACUC (Institutional Animal Care and Use Committee) of Tsinghua University and performed in accordance with guidelines of the IACUC. The laboratory animal facility of Tsinghua University has been accredited by AAALAC (Association for Assessment and Accreditation of Laboratory Animal Care International).
Mouse genotyping
Genomic DNA was extracted from mouse tails, PCR was performed with 2 3 Taq Plus MasterMix (Dye) (Cwbiotech). Amplicons were analyzed by agarose gel electrophoresis and Sequencing. PCR primers and expected amplicon sizes for OT-I, OT-II, ASC À/À , Mefv À/À , Caspase1 À/À /11 À/À , Myd88 À/À , Trif lps2/lps2 , GGPPS fl/fl , CD11c-Cre and CD11c-DTR are indicated in following tables.
Genotyping Primers for OT-I:
Genotyping Primers for OT-II: Genotyping Primers for ASC À/À :
Genotyping Primers for Mefv À/À :
Genotyping Primers for Caspase1 À/À /11 À/À :
Genotyping Primers for Myd88 À/À : Genotyping Primers for CD11c-Cre:
Genotyping Primers for CD11c-DTR:
Monkey
Cynomolgus monkeys (Macaca fascicularis, male) with age of 3-3.5 years and an average weight of 3.5 ± 0.5 kg were selected for the vaccination experiment. The selected monkeys met the national animal quality standards (BV, SRV, STLV, SIV, Salmonella and Shigella negative), and have not received any drug test before and haven't been immunized within three months. All monkeys were monitored for general health and quarantined for 2 weeks before the study. Monkeys were housed in individual cages (0.95 m height, 0.9 m depth, 0.8 m width) under controlled conditions of humidity (40%$70%), temperature (20$25 C), and light (12 h light/dark cycle, lights off at 8:00 p.m.) in Laboratory Animals Center of the Academy of Military Medical Sciences. Animals were given free access to water and were fed twice daily on a diet of fresh fruits, fresh vegetables and monkey chow. The experimental procedures were approved by the Ethical Committee for Animal Experimentation at Laboratory Animals Center of the Academy of Military Medical Sciences.
Cell lines B16-OVA, a B16 cell line (mouse, male) transfected with expression vectors encoding OVA (Falo et al., 1995) , was generously provided by Prof. Xiaoming Gao, Soochow University. TC-1 cell, a C57BL/6 mouse lung epithelial line transformed with human papillomavirus 16 E6/E7 (sex not reported) (Lin et al., 1996) , was purchased from Innovate Biotech. B16-F10 (mouse, male) was kindly provided by Prof. Xuebin Liao, Tsinghua University. B16-OVA, TC-1 and B16-F10 cell lines were cultured in Dulbecco's Modified Eagle's medium (DMEM) (Gbico) supplemented with 10% heat inactivated FBS (BioInd), 1% penicillin/streptomycin (Beyotime) at 37 C and 5% CO 2 .
METHOD DETAILS
Reagents
All adjuvants were purchased from Sigma-Aldrich, unless specified otherwise. Fluvastatin, pitavastatin, and rosuvastatin were from Central China Genetic Technology. Lipophilic statins (e.g., simvastatin) were provided as solid powder and then stored in DMSO as a 10 mg/mL solution at À80 C. Since lipophilic statins are not soluble, 100 mL volume containing 80mL PBS, 10 mL statins in DMSO and 10 mL antigen in PBS was homogenized using regulated shaker just prior to delivery, and the control group uses 10 mL DMSO plus 90mL PBS. Imject Alum and Rab5 SiRNA were purchased from Thermo Fisher Scientific. Polyethyleneimine was from Labcost S&T. Squalene-water emulsion (MF-59), consisting of 4.3% squalene, 0.5% Tween 80, and 0.5% Span 85 in citrate buffer (all Sigma-Aldrich), was prepared by homogenization at 12,000 psi with a micro-fluidizer (Calabro et al., 2013) . Alexa488-Dextran and CpG ODN 1826 was purchased from Invivogen. LPS and ovalbumin (OVA) were purchased from Sigma-Aldrich. HBsAg was a gift from Professor Ningshao Xia of Xiamen University. E7 was purchased from Genscript. A recombinant influenza A (PR8 H1N1) hemagglutinin globular domain HA1 (amino acids 11-324) was prepared according to published procedures . NP-KLH and NP-BSA were from Santa Cruz Biotechnology. Human FPPS/GGPPS inhibition assay and crystallization of human FPPS with TH-Z93 Human FPPS and GGPPS were expressed, purified, and used for enzymatic inhibition assays as previously described (Zhang et al., 2009) . Co-crystallization of human FPPS with TH-Z93 was carried out as follows. 20 mg/mL HsFPPS was mixed with 1 mM TH-Z93 and 2 mM MgCl 2 . The mixture was then incubated at 4 C overnight. The mixture was centrifuged and any precipitate discarded. The protein solution was then mixed with mother liquor (1.2 M Na/K phosphate, pH 5.2 and S10 25% glycerol) in a ratio of 1:1. Hanging drops were incubated at 18 C. Large, hexagon-like crystals appeared in 1-3 days and grew to maximum size in one week. The crystals were mounted, then frozen in liquid nitrogen. Diffraction data was collected at the Shanghai Synchrotron Radiation Facility (SSRF). Data was processed by using HKL2000 (Otwinowski and Minor, 1997) and refined by using Refmac5 (Murshudov et al., 2011) and Coot7 (Emsley and Cowtan, 2004) . Refinement statistics are shown in Table S1 . Graphics were created by using PyMOL (http://pymol.sourceforge.net/).
Mouse immunizations
Mice were vaccinated with a prime-boost regimen: animals were primed on day 0 with antigen e.g., OVA (100 mg) alone or with different adjuvants suspended in PBS with a final injection volume 100 mL. In some cases, immunization was boosted later. All injections were performed intramuscularly (i.m.), unless stated otherwise.
Antibody titer and avidity testing Serum samples were collected from whole blood by centrifugation and stored at À80 C. Antigen-coated and blocked ELISA plates (Nunc) were incubated with serial dilutions of samples. ELISA plates were coated with OVA, HBsAg, HA1, E7, or NP-BSA in carbonate buffer (pH = 9.6) at 4 C, overnight. After drying, plates were blocked with 2% BSA in PBS for 2 h at 37 C. After washing, 100 mL of diluted serum was added in triplicate wells, followed by incubation for 2 h at 37 C. Plates were then washed with PBST (0.05% Tween20, Sigma-Aldrich, in PBS), and were incubated with HRP-labeled goat anti-mouse IgG(H+L), IgG1, IgG2a, IgG2b, IgG2c or IgG3 antibodies (All from Southern Biotech) for 1 h at 37 C. Ortho-phenylenediamine (Sigma-Aldrich) substrate was added (100 mL/well) and the plates were incubated for 15 min at room temperature, followed by the addition of H 2 SO 4 (50 mL, 2 M) per well to terminate the reaction. Optical density (OD) was immediately read at 492 nm using an ELISA plate reader (Bio-Rad). Antibody titers were obtained by plotting the maximum serum dilution that gave an optical density > 2 3 background (Kim et al., 2015) . The avidity index was determined by diluting immune serum to a concentration that corresponded to an OD = 3.0 in an endpoint ELISA; serum samples were then reacted with antigen-coated plates for 2 h at 37 C. After washing, various concentrations (0.5 M-5.5 M) of the chaotropic reagent sodium thiocyanate (100 mL/well) were added. 20 min later, the plates were washed and dried, the remaining plate-bound antibodies measured. The avidity index is the concentration of chaotrope required to reduce the optical density (OD) by 50% compared to that in wells without the chaotrope (Hong et al., 2010) .
Germinal center formation C57BL/6 mice were immunized with OVA (100 mg) alone or in combination with simvastatin (100 mg) or Alum (2 mg). DLNs were isolated on day 10 after vaccination. Single-cell suspensions were prepared in PBS containing EDTA (2 mM), by gentle grinding. Cells were then passed through a nylon sieve to remove aggregates. Cells were stained with phycoerythrin (PE)-labeled anti-mouse B220 (Biolegend), allophycocyanin (APC)-labeled anti-mouse Fas (Ebioscience) and FITC-labeled anti-mouse GL7 (Biolegend) for 30 min on ice. Cells were washed and assessed by flow cytometry.
Virus challenge and analyses C57BL/6 mice were immunized with a single dose of 5 mg influenza A (PR8 H1N1) HA1 alone or combined with an adjuvant, and boosted on days 14 and 21 with HA1 (5 mg). In experiments shown in Figure S1M -S1N, simvastatin alone (20 mg) was given to C57BL/6 mice on day 0, 14 and 21. Anesthetized mice received viral challenge on day 28 with live influenza A PR8 virus (40 mL, 0.3 U/mL) in endotoxin-free PBS. Following challenge, mice were monitored for 15 days for survival, body weight changes, and clinical signs of illness (Shirey et al., 2013) . Mice that lost > 30% of their original weight were euthanized. A disease score ranging from 0 (no symptoms) to 5 (moribund) was recorded daily (Tate et al., 2008) .
Mice were sacrificed 5 days after influenza A (PR8) challenge, and lungs were perfused and fixed with 4% paraformaldehyde (PFA, Twbio). Fixed lungs were embedded in paraffin and cut into 8 mm sections. Sections were stained with hematoxylin and eosin (H&E), then read under double-blind conditions. Cynomolgus monkey immunization with simvastatin and HA1 9 healthy cynomolgus monkeys (male) with an average weight of 3.5 ± 0.5 kg and an average age of 3-3.5 years, were selected. They have not received any drug test before and haven't been immunized within three months. Each 1 mL dose of the vaccines: HA1 (50 mg); HA1 (50 mg) combined with simvastatin (100 mg), or HA1 combined with Alum (2 mg), was administered i.m. into the lateral aspect of the thigh. The primary vaccination schedule consisted of a series of three injections, administered on days 0, 14, and 28. Blood samples were collected before the first vaccination and every week after vaccination. The serum was then separated and stored at À70 C for antibody analysis.
Toxicity assessment of simvastatin-mediated vaccination C57BL/6 mice were vaccinated on day 0 with OVA (100 mg) alone or in combination with simvastatin (20 mg, 100 mg or 500 mg), and boosted on day 7 and day 14. Their mortality and body weight monitored during the entire time course. On day 40, hearts, lungs, livers, kidneys, spleens and ipsilateral lymph nodes were removed and organ weights were recorded. Spleen and lymph node single-cell suspensions were prepared in PBS containing EDTA (2 mM) by gentle grinding. Cells were then passed through a nylon sieve to remove aggregates. B cells percentage was detected by staining with PE labeled anti-mouse B220 (Biolegend); T cells percentage was detected by staining with APC labeled anti-mouse CD3 (Miltenyi); neutrophil percentage was detected by staining with FITC labeled anti mouse Gr-1 (Miltenyi) and PE labeled anti-mouse CD11b (Biolegend); macrophages percentage was detected by staining with FITC labeled anti mouse F4/80 (Miltenyi) and PE labeled anti-mouse CD11b (Miltenyi); dendritic cells percentage was detected by staining with PE labeled anti-mouse CD11c (Biolegend). Cell staining was done at 4 C, for 30 min and examined by flow cytometry.
In vivo T cell activation C57BL/6 mice were immunized with simvastatin (100 mg) and OVA (100 mg). After 24 h, DLNs were removed for analysis. Single-cells were isolated and then stained. CD4 + and CD8 + T cells cell-surface CD69 molecule was detected by APC labeled anti-CD3 (Miltenyi), PE labeled anti-CD4 (Biolegend) or PE labeled anti-CD8 (Biolegend) and FITC labeled anti-mouse CD69 (Miltenyi).
Preparation of immature BMDCs
Bone marrow cells were isolated from C57BL/6 mice and cultured in RPMI 1640 media (GIBCO) supplemented with 10% heat inactivated FBS (BioInd), 1% penicillin/streptomycin (Beyotime), 20 ng/mL of IL-4 (Peprotech)and 20 ng/mL of GM-CSF (Peprotech) at 37 C and 5% CO 2 . Non-adherent cells were harvested on day 7 and used immediately. DC purity was confirmed with PE labeled antimouse CD11c (Biolegend) by FACS, consistently found to be > 90% CD11c + .
In vitro BMDC stimulation Immature BMDCs (5 3 10 4 ) were planted onto 96 well plates, then treated with simvastatin (1 mM) or LPS (100 ng/mL) for 24 h. The cell supernatants IL-6 was measured by mouse IL-6 ELISA kit (Ebioscience), TNF-a was measured by mouse TNF-a ELISA kit (Ebioscience) and IL-12p70 was measured by mouse IL-12p70 ELISA kit (Ebioscience) according to the manufacturer's instructions. Cell-surface co-stimulatory molecules and MHC-II were detected by FITC labeled anti-mouse CD80 (Biolegend), anti-mouse CD86 (Biolegend) and PE labeled anti-mouse MHC-II (Ebioscience).
Pyrin inflammasome activation
Immature BMDCs from Wild-type (WT), Mefv À/À , ASC À/À and Caspase 1 À/À /11 À/À mice (5 3 10 4 ) were planted on 96 well plates, and pretreated with 1 mM simvastatin for 24 h, followed by addition of 100 ng/mL LPS for another 24 h. Cell supernatant IL-1b was measured by mouse IL-1b ELISA kit (Ebioscience) according to the manufacturer's instructions.
Endosomal trafficking
BMDCs were plated at low density (less than 40% confluence) on sterile coverslips and pre-treated with simvastatin (1 mM) or Rab5 siRNA for 24 h. Alexa488-Dextran (Invitrogen) (100 mg/mL) and Lysotracker Red DND-26 (Life Technologies) (1 mM) were then added to cells for incubation (10 min) at 37 C. Cells were then washed and fixed in 2% PFA (Twbio) in PBS for 15 min at 37 C, followed by permeabilization buffer (Biolegend) for 5 min at 37 C. Cells were mounted with DAPI-Fluoromount-G (SouthernBiotech) and imaging carried out by using a confocal microscope (Zeiss 780).
Vaccination mediated by simvastatin pretreated BMDCs B16-F10 tumor cells (3 3 10 5 ) were injected subcutaneously into the right flanks of C57BL/6 mice. BMDCs were treated with simvastatin (1 mM) for 24 h, then pulsed with TRP2 protein (50 mg/mL) for 8 h. Cells were then washed with PBS and injected into mice on day 3 and day 7 after tumor inoculation. Tumor volumes were measured twice a week.
Antigen uptake and degradation BMDCs (5 3 10 4 ) were treated with simvastatin (1 mM) for 24 h and were then incubated with 5 mg/mL FITC labeled OVA (Solarbio). Cell fluorescence intensities were measured after 5 min, 10 min, 15 min and 30 min. 30 min later, excess antigen was removed by washing and cells were fixed with 1% PFA (Twbio) and mounted with DAPI-Fluoromount-G (SouthernBiotech). Cell imaging was carried out using a confocal microscope, with cell fluorescence intensities being measured at the time points indicated.
In vivo antigen retention assay C57BL/6 mice were immunized intramuscularly with FITC-OVA (100 mg) alone or in combination with simvastatin (100 mg). 24 h later, DLNs were removed for analysis. Single-cell suspensions were prepared in PBS-EDTA (2 mM) by gentle teasing, then cells were passed through a sieve to remove aggregates. Cells were then stained for DC with PerCP labeled anti mouse CD45 (Miltenyi) and PE labeled anti-mouse CD11c (Miltenyi), and examined by FACS. FITC-OVA-positive gates were based on the 'no antigen' control group and were compensated for nonspecific fluorescence. Absolute cell numbers were determined in parallel by flow cytometry using Liquid Counting Beads (BD).
In vivo macrophage and dendritic cell depletion Macrophages were depleted by clodronate liposome (Target Technology) via tail intravenous injection (50 mL) and subcutaneous injection in the vicinity of lymph nodes (50 mL 3 2) 48h before immunization. DCs reduction was achieved by intraperitoneal injection of diphtheria toxin (50 ng) (Fitzgerald) in CD11c-DTR transgenic mice, 24 h prior to immunization. Macrophage and dendritic cell depletion efficiency was detected by staining with FITC-labeled anti mouse F4/80 (Miltenyi) and PE labeled anti-mouse CD11c (Biolegend), and examined by flow cytometry.
Cell extraction and peptide separation
BMDCs were grown to a density of 10 6 cells/mL with less than 5% cell death. Cells were then treated with 1 mM simvastatin for 24 h. Next, cells were incubated with 100 mg/mL OVA for 8 h. Cells (10 8 ) were washed once with PBS, then were lysed in 0.1% trifluoroacetic acid (J&K Chemicals) in water by vigorous vortexing for 1 min. Another 15 mL of 1% trifluoroacetic acid was then added to the lysates which were kept on ice for 30 min with brief vortexing every 5 min. After centrifugation at 28,000 rpm at 4 C, the supernatants were lyophilized, then re-dissolved in 0.15% trifluoroacetic acid and centrifuged through Centricon 10 filters (Merck Millipore). The filtrates were again lyophilized and re-dissolved in 100 mL RPMI 1640 media. CD4 + and CD8 + T cells were purified from OT-I or OT-II transgenic mice spleens using aCD4 or aCD8-microbeads (Miltenyi), as per the manufacturer's instructions. Peptide incubation mixtures were transferred to 96-well plates at 50 mL per well, and another 5 3 10 4 purified OT-I CD8 + T or OT-II CD4 + T cells and 5 3 10 4 DCs in 150 mL media were added to each well. Cells were cultured for 24 h, and the IFN-g content in supernatant samples measured by using mouse e IL-6 ELISA kit (Ebioscience).
Cell surface MHC epitope staining BMDCs (2 3 10 5 ) were planted on 24 well plates, and cells were treated with simvastatin (1 mM) for 24 h and then treated with OVA (100 mg/mL) for another 12 h. Cells were harvest and detected by APC labeled anti-mouse CD11c and PE labeled 25D1 antibody to identify the OVA257-264/H-2Kb complex on the DC surface (Biolegend).
Dendritic cell fixation and antigen-presentation 5 3 10 4 DCs (pretreated with 1 mM simvastatin for 24 h) were pulsed with OVA (100 mg/mL for another 12 h). Cell fixation was performed by incubation for 10 minutes at room temperature in 4% PFA (Twbio) in PBS followed by 3 washes. Fixed cells were plated in round-bottom 96-well plates and then incubated with 5 3 10 4 OT-I or OT-II cells for 24 h at 37 C. Supernatant IFN-g was detected using mouse IFN-gELISA kit (Ebioscience).
Mass spec: parallel reaction monitoring analysis
We selected ovalbumin peptide SIINFEKL as standards to verify retention time and m/z for further targeted LC-MS/MS analyses using parallel reaction monitoring (PRM). Cell extraction and peptide separation were described before, and these samples were resuspended in 20 mL water containing 0.1% formic acid for LC-MS/MS analysis.
For LC-MS/MS analysis, the peptides were separated by a C18 column (75 mm inner-diameter, 150 mm length, 5 mm, 300 Å ) with a Thermo-Dionex Ultimate 3000 HPLC system, which was directly connected with a Thermo Scientific Q-Exactive HF-X mass spectrometer. For each analysis, 2 mL of each sample was separated by adjusted gradients with a flow rate of 3 mL /min. The mass spectrometer was programmed to acquire in parallel reaction monitoring (PRM) acquisition mode. For ionization, 2500 V was applied and a 250 C capillary temperature was used. All samples were analyzed using an acquisition method that combined a full scan event followed by 1 PRM scan as triggered by an unscheduled inclusion list containing the target precursor ions of peptide SIINFEKL. The full scan event was collected using a m/z 150-2,000 mass selection, a resolution of 60,000 (at m/z 400), target automatic gain control (AGC) value of 3 3 10 6 and a maximum injection time of 200 ms. The PRM scan events used an Orbitrap resolution of 15,000, an AGC value of 2 3 10 6 and maximum fill time of 100 ms with an isolation width of 2 m/z. Fragmentation was performed with a normalized collision energy of 27.
PRM data analysis was performed using Xcalibur 3.1.0 software. The peak areas of three ragmented ions with highest intensity in MS/MS spectra were used to calculate peptide ratio. For sequence SIINFEKL, y2 ion (m/z = 536.3079), y5 ion (m/z = 650.3508) and y6 ion (m/z = 763.4349) were used for quantification.
T cell activation and proliferation assays CD4 + and CD8 + T cells were purified from OT-I or OT-II transgenic mice spleens using aCD4 or aCD8-microbeads (Miltenyi), as per the manufacturer's instructions, then were labeled with carboxyfluorescein succinimidyl amino ester (CFSE) (KeyGen Biotech). For antigenic stimulation, a total of 5 3 10 4 purified T cells and 5 3 10 4 DCs (pretreated with 1 mM simvastatin for 24 h and then washed) pulsed with OVA (100 mg/mL) were mixed in each well of a 96-well plate, in triplicate, for 72 h at 37 C. Supernatant IFN-g was measured by using mouse IFN-g ELISA kit (Ebioscience).
DLN cell re-stimulation and proliferation C57BL/6 mice were vaccinated on day 0 and boosted on day 14 and day 21. On day 28, 2 3 10 5 DLN cells were cultured in the presence or absence of antigen (100 mg/mL) for 72 h in 96-well plates (200 mL per well). Cells were pulsed with 1 mCi of [ 3 H] thymidine (Perkin-Elmer) per well for the last 12 h of incubation. Data are expressed as counts per minute (c.p.m.). Cytokine profiling was performed on supernatants 72 h after antigen-restimulation using a CBA assay kit (BD-PharMingen), according to the manufacturer's instructions.
In vivo cytotoxicity assays C57BL/6 mice were vaccinated on day 0 with OVA (100 mg), alone or in combination with simvastatin (100 mg), CpG (100 mg) or Alun (2mg), and boosted on day 14 and day 21. On day 28, vaccinated animals were intravenously injected with 1 3 10 7 donor splenocytes from naive C57BL/6 mice, and half of the cells were pulsed with 5 mM SIINFEKL peptide (corresponding to OVA257-264) for 2 h. Prior to injection, peptide-pulsed and antigen-free cells were labeled with either 1 or 10 mM CFSE. Cells were then washed twice with PBS and mixed 1:1 with PBS, in preparation for transfer into immunized recipients. 18 h after transfer, immunized recipients were sacrificed and splenocytes analyzed by using flow cytometry to quantify the ratio of peptide-pulsed to non-pulsed donor cells present. Specific killing was defined as the percentage of specific lysis = transferred control ratio -experimental ratio 3 100 (Clemente et al., 2013) .
Tetramer staining H2-K b /OVA tetramer assays were used to detect OVA-specific CD8 + T cells. C57BL/6 mice were immunized with OVA (100 mg) and simvastatin (100 mg), Alum (2 mg) or CpG (100 mg), followed by boosting with OVA (50 mg) on days 7 and 14. On day 21,splenocytes from immunized mice were double stained with FITC-labeled anti mouse CD8 (Biolegend) and PE-labeled H2-K b /OVA (SIINFEKL) tetramers (MoBiTec GmbH). Cell staining was done at 4 C, for 30 min with 1 mL of anti-CD8 antibody and 10 mL of OVA tetramers per 10 6 cells, according to the manufacturer's instructions.
Therapeutic cancer vaccination C57BL/6 mice were inoculated subcutaneously on the right hind flank with 3 3 10 5 B16-OVA cells. Tumors were allowed to establish for 5 days before treatment. Tumor-bearing mice were randomized into groups and vaccinated on day 5, 12 and 19 with one of: 100 mg of OVA, combined with 20 mg simvastatin; 20 mg TH-Z93; 20 mg TH-Z145 or 20 mg CpG. For the PD-1 blockade experiments, a-PD-1 (Bioxcell) (100 mg per mouse per injection) was injected intra-peritoneally, twice a week, after vaccination.
For TC-1 tumors, C57BL/6 mice were inoculated subcutaneously on the right hind flank with 3 3 10 5 TC-1 cells (a murine lung epithelial line transformed with human papillomavirus 16 (HPV-16) E6/E7). Tumors were allowed to establish for seven days before treatment. Tumor-bearing mice were randomized into groups and treated on days 7, 14, and 21 (20 mg of E7, combined with 20 mg simvastatin; 20 mg TH-Z93; 20 mg TH-Z145 or 20 mg CpG). The PD-1 blockade experiments were performed as described above. For the TC-1 re-challenge model, mice were analyzed for the presence of tumors and survival on day 50 after tumor cell inoculation. One hundred days after the first round of tumor cell inoculation, mice were re-challenged with 3 3 10 5 TC-1 tumor cells.
To deplete CD4 + T cells, CD8 + T cells and NK cells, 100 mg of anti-CD4 (Biolegend), anti-CD8 (Biolegend) and anti-NK1.1 (Clone: PK136) antibodies were given via intraperitoneal injection 24 h before immunization. Depletion efficiency was monitored weekly for at least three weeks.
Tumor sizes were measured every 2 days by using electronic calipers and given as length (mm) 3 width (mm) 3 width (mm)/2. Mice with tumors larger than 20 mm on the longest axis were euthanized. IVIS images were captured with a Caliper IVIS Lumina II (Caliper Life Sciences) instrument following light anesthesia with isoflurane, and intraperitoneal injection of D-luciferin (Gold Biotechnology) (0.5 mg/g per mouse). Images were quantified using Living Image 4.0.
Tumor infiltrating T cell analysis C57BL/6 mice were inoculated subcutaneously on the right hind flank with 3 3 10 5 B16-OVA cells. Tumors were allowed to establish for 5 days before treatment. Tumor-bearing mice were randomized into groups and vaccinated on day 5 (100 mg of OVA, 20 mg simvastatin). Tumor tissues were collected on day 11 and bisected and one half was incubated in a PBS solution containing Collagenase P (0.2 mg/mL), Dispase II (0.8 mg/mL), DNase I (0.01mg/mL), and Collagenase A (0.3 mg/mL) for 60 min at 37 C under gentle rocking. Digestion was stopped by adding FBS on ice. The supernatants were centrifuged at 4000 rpm for 10 min at 4 C. The samples were then resuspended in 1 mL PBS and filtered through a nylon sieve, followed by a washing step in PBS (4000 rpm for 10 min at 4 C). The cells were resuspended in 10 mL red blood cell lysis buffer and incubated for 10 min at 37 C, followed by a washing step in PBS phase B consisted of acetonitrile at pH 10 (adjusted again with ammonium hydroxide). The solvent gradient was as follows: 5%-8% B, 5 min; 8%-18% B, 25 min; 18%-32% B, 32 min; 32%-95% B, 2 min; 95% B, 6 min; 95%-5% B, 5 min. Peptides were monitored at 214 nm and were collected every 90 s.
For liquid chromatographyÀtandem mass spectrometry (LCÀMS/MS) analysis, the TMT-labeled peptides were separated by using a 120 min gradient elution at a flow rate 0.300 mL/min with the EASY-nLC 1000 system which was directly interfaced with a Thermo Orbitrap Fusion mass spectrometer. The analytical column was a fused-silica capillary (75 mm ID, 150 mm length; Upchurch, Oak Harbor, WA) packed with C-18 resin (300 Å , 5 mm; Varian, Lexington, MA). Mobile phase A consisted of 0.1% formic acid, and mobile phase B consisted of 100% acetonitrile and 0.1% formic acid. An Orbitrap Fusion mass spectrometer was operated in the data-dependent acquisition mode using Xcalibur3.0 software. There was a single full-scan mass spectrum in the Orbitrap (350-1550 m/z, 120,000 resolution) followed by 20 data-dependent MS/MS scans in an ion routing multipole at 38% normalized collision energy.
MS/MS spectra from each LCÀMS/MS analysis were searched against the mouse database using the Sequest HT algorithm in Proteome Discoverer software (PD, version 1.4). The search criteria were as follows: full tryptic specificity was required; one missed cleavage was allowed; the oxidation (M) was set as a variable modification; carbamidomethylation (C) and TMTsixplex (K and N-terminal) were set as fixed modifications; precursor ion mass tolerance was set at 20 ppm for all MS and 20 mmu for all MS/MS spectra. The peptide false discovery rate was calculated using Percolator provided by PD 1.4. When the q-value was smaller than 1%, the peptide spectrum match was considered to be correct. Relative protein quantification was performed using PD software according to the intensity of the TMT reporter ions. Quantitation was carried out only for proteins with two or more unique peptide matches. Peptides only assigned to one given protein group were considered as unique. Protein ratios were calculated as the median of all peptide hits belonging to a protein. Quantitative precision was expressed as protein ratio variability.
QUANTIFICATION AND STATISTICAL ANALYSIS
All results are expressed as the mean ± SEM. Unpaired two-tailed t tests were used for comparison of two groups. A two-way ANOVA was performed when both time and treatment were compared. For the survival studies, a Log-Rank (Mantel-Cox) test was used. p < 0.05 was considered statistically-significant and denoted as follows: *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. Statistical analyses were performed by using GraphPad PRISM. Figures 6 and 7 but with TH-Z93 or TH-Z145 as adjuvant. Tumor volumes were recorded after tumor inoculation at the times indicated. Tumor volume and Kaplan-Meier survival plots in the B16-OVA model (n = 10). (C and D) Tumor volume and Kaplan-Meier survival plots in the TC-1-E7 model. a-PD-1 (100 mg per mouse per injection) was injected intra-peritoneally twice a week following vaccination (n = 10). All data are representative of at least three independent experiments. Tumor volume data were analyzed by using a two-way ANOVA (A, C) and survival data were analyzed by using a log-rank (Mantel-Cox) test (B, D) . ****p < 0.0001. All error bars denote the SEM.
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